Cocrystal pharma submits pre-investigational new drug briefing package to the fda for clinical development guidance of cdi-45205 for covid-19 treatment

Fda 's response is expected to provide greater clarity and guidance on designing phase 1 and phase 2 clinical trials for cdi-45205

COCP Ratings Summary

COCP Quant Ranking